US 11,497,781

Application 16/083,709 · Granted Nov 15, 2022

Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus cg0070 and an immune checkpoint inhibitor

Estimated expiration

March 9, 2037

10y 111d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Mar 9, 2017
+ 20 years
Mar 9, 2037
PTA +0d
Mar 9, 2037
No TD
—
Final
Mar 9, 2037

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
September 10, 2018
Earliest effective filing
March 9, 2017
Issue date
November 15, 2022
PTA
0 days
Base expiry (before PTA)
March 9, 2037

March 9, 2017 + 20 years = March 9, 2037

  • National stage entry of application PCTUS2017021694, filed Mar 9, 2017
  • PRO62/306,470 — Provisional — not used for base term
  • PRO62/306,470 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 16/083,709 · US 11,497,781

PatentReply compiles the prosecution history behind US 11,497,781: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11497781

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.